Denmark's Novo Nordisk 2025 sales rise 10% at CER

Overview

• Denmark healthcare firm's 2025 sales grew 10% at constant exchange rates, driven by obesity care growth

• Operating profit for 2025 rose 6% at CER and declined 1% in Danish kroner

• Company announced DKK 15 bln share repurchase program

• Board will propose a final dividend of DKK 7.95 per share for 2025 at AGM on March 26

Outlook

• Novo Nordisk expects 2026 adjusted sales growth to be -5 to -13% at CER

• Company anticipates 2026 adjusted operating profit growth of -5 to -13% at CER

• Sales outlook impacted by lower prices and competition, but new treatments to expand reach

Result Drivers

• OBESITY CARE GROWTH - Sales within obesity care increased by 26% in Danish kroner, driven by the launch of Wegovy pill and strong prescription uptake

• TRANSFORMATION COSTS - Operating profit impacted by DKK 8 bln costs related to company-wide transformation, without which operating profit would have risen 6% in DKK

• R&D DEVELOPMENTS - Key R&D developments included successful trials for diabetes and obesity treatments, contributing to future growth prospects

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 13 "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Novo Nordisk A/S is DKK402.50, about 7.9% above its February 2 closing price of DKK373.05

• The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nGNE2Mtp22

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)